

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERA

NERPHARMA

SIMIS

NMS Group S.p.A. Appoints Andrew Curtis as Chief Strategy Officer, Effective Immediately

Nerviano, 3 August 2022

NMS Group S.p.A, an oncology R&D powerhouse with a biotech discovering and developing innovative therapies for the treatment of cancer, a CRO and CDMO that together push Oncology Forward, has announced the appointment of Andrew Curtis as Chief Strategy Officer reporting to the Group CEO, effective immediately. Andrew brings to NMS Group three decades of experience as a global corporate strategy and business leader from biotech and pharma sectors. He is based in the US, working from the US subsidiary (Nerviano Medical Sciences Inc.) in Boston just opened this month.

“We have been transforming the group and making significant progress at NMS, leveraging our proprietary kinase platform and our ADC technology to identify and advance a very exciting pipeline of oncological therapeutic candidates,” said Hugues Dolgos, PharmD chief executive officer of NMS Group. “We are very excited to have Andrew on board. With his expertise and impressive track record, we sure will push our pipeline forward, advancing internally and through partnerships with accelerated pace to bring treatment to patients in need. Also, Andrew will be of great help to turn our CRO and CDMO businesses more prosperous and robust.”

“I’m thrilled to join NMS at this stage in its journey,” said Andrew. “I look forward to working with the team, both in Italy and the US to build on the strong foundation and further outline and implement strategies to all subsidiaries to create value for our clients, our investors and change the future of many individuals with our cure.”

As chief strategy officer, Andrew will be responsible for both leading the group-wide strategy formulation and execution and further building commercial forces and strategic alliances globally. He will play a key role in our future IPO roadmap and turn the NMS Group campus in Nerviano a center of oncology and biotech excellence with top-tier players.

Andrew joins NMS from Artelus (Bethlehem, PA) where he was President and CEO, responsible for leading this AI/Deep Learning company focus on the development of proprietary AI algorithms. Prior to this role, he held key positions in business development and licensing with GNS Healthcare (Somerville, MA), SUDA Pharmaceuticals (Perth, Australia, & Center Valley PA) and Affimed (Heidelberg, Germany & Doylestown, PA), where he sealed licensing, product and development agreements, and established concrete collaborations with Sanofi, Merck, MD Anderson and the like. During his multiyear tenure at Pfizer (NY, NY), Andrew held leading roles to establish and develop the rare disease business through major M&A, closed key strategic alliance and licensing agreements and fortify its external collaborations as well as internal capability development.

###

About NMS Group

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERERA

NERPHARMA

SIMIS

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

The NMS Group has three subsidiaries. NMS Srl is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it